209 related articles for article (PubMed ID: 30776136)
1. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.
George G; Scailteux LM; Garmo H; Balusson F; Cardwell C; Coster G; Schutter H; Kuiper JG; McMenamin Ú; Verbeeck J; Van Hemelrijck M
Fundam Clin Pharmacol; 2019 Aug; 33(4):479-499. PubMed ID: 30776136
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
Davey P; Kirby MG
World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
5. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
7. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
8. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
10. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.
Lin E; Garmo H; Van Hemelrijck M; Zethelius B; Stattin P; Hagström E; Adolfsson J; Crawley D
JAMA Netw Open; 2022 Aug; 5(8):e2225600. PubMed ID: 35939302
[TBL] [Abstract][Full Text] [Related]
11. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
12. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis.
Gu L; Li X; Liu W
Front Endocrinol (Lausanne); 2023; 14():1157857. PubMed ID: 37065739
[TBL] [Abstract][Full Text] [Related]
13. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
[TBL] [Abstract][Full Text] [Related]
15. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone antagonist: A real advantage?
Kimura T; Sasaki H; Akazawa K; Egawa S
Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
[TBL] [Abstract][Full Text] [Related]
17. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
18. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
19. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
20. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden.
George G; Garmo H; Rudman S; Holmberg L; Robinson D; Stattin P; Adolfsson J; Van Hemelrijck M
Scand J Urol; 2020 Feb; 54(1):20-26. PubMed ID: 31842658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
